Dr. Sennewald Medizintechnik GmbH

Dr. Sennewald Medizintechnik has over 30 years of experience in the sale of medical technology. In the context of regional and local hyperthermia in clinical oncology, the company entered into a long-term partnership with the pioneer and world market leader, Pyrexar Medical, to further develop the manufacture of hyperthermia systems. The companies ties to the scientific community have led to the acceptance of hyperthermia, development of certified software, reimbursement of hyperthermia and its use in pediatric treatment. Phase III studies show that Pyrexar systems lead to a significant increase in cancer response rates. In addition, these systems are the only...

Hyperthermie,medizintechnik,regionale krebstherapie,onkologie,hyperthermia,clinical oncology,radiotherapy,cancer treatment,chemotherapy,radiation oncology,immmunotherapy,radiative hyperthermia,clinical studies,cancer research,thermal medicine,medical device,thermal oncology,soft tissue sarcoma,neuroradiology,flash,and swoop

Dr. sennewald medizintechnik gmbh operates in the Medical equipment manufacturing industry.

Dr. sennewald medizintechnik gmbh's revenue is 11m - 100m

Dr. sennewald medizintechnik gmbh has 11 - 50 employees.